MUSCLE WASTING AND CARDIAC MUSCLE DAMAGE IN CACHECTIC PATIENTS by Sangiorgi, C. et al.
MUSCLE WASTING AND CARDIAC MUSCLE DAMAGE IN CACHECTIC PATIENTS 
 
Claudia Sangiorgi, Filippo Macaluso, Rosario Barone, Elisa Dino, Valentina Di Felice 
Introduction 
Muscle wasting is a weakening, shrinking, and loss of muscle caused by a disease or lack 
of use. It causes a decrease in strength and inability to move compromising the quality of 
life. Muscle wasting can be caused by cachexia, sarcopenia or anorexia. Cachexia is a 
condition associated with a number of chronic diseases and acute medical conditions 
where patients are often hospitalized or become extremely inactive. Some of the diseases 
that bring to cachexia are amyotrophic lateral sclerosis, multiple sclerosis, muscular 
dystrophy, neuropathy, polio, spinal muscular atrophy, cancer, acquired immunodefi-
ciency syndrome (AIDS), congestive heart failure, chronic obstructive pulmonary disease 
(COPD), renal failure and other illnesses that lead to a chronic inflammation state (1). 
Sarcopenia lies in aging, it shows a decrease in skeletal muscle mass due to decreased 
physical activity and production of anabolic hormones. Anorexia results by lower energy 
intake often due to loss of appetite. Malnutrition can be present in cachexia. However, 
unlike other diseases related to this cause, cachexia represents a disturbed metabolic 
panel and it cannot be treated with nutrition alone (1). 
Cachexia, sarcopenia and anorexia may cause both muscle wasting and damage to the 
cardiac muscle. In this review we point out our attention on muscle wasting and heart 
failure mainly caused by cachexia. 
 
Definition of cachexia 
The definition that scientists and clinicians agreed in the cachexia consensus conference 
in 2007 in Tampa (FL) describes cachexia as a “complex metabolic syndrome associated 
































































































































Muscle wasting is a degeneration of the muscle tissue that can derive from several patho-
logical situations, but most of the times is caused by a condition of cachexia in patients 
with cancer or other diseases. This degeneration results from a decrease in protein syn-
thesis and an increase in protein degradation. This is caused mainly by the overexpres-
sion of ubiquitin-proteosome-system (UPS) elements, under the control of factors re-
leased in cachexia that lead cells toward a catabolic rather than an anabolic pathway. 
Both skeletal and cardiac muscles can be affected by muscle wasting and until now an 
effective treatment is unknown. Only experimental trials of exercise training bring to a 
recovery of mass loss, but many researchers think that a potential future treatment may 
be represented by stem cells. 
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Cachexia may be caused by chronic infec-
tion, nutritional deficiencies, heart failure, 
rheumatoid arthritis, COPD, parasitic dis-
eases, disease of the gastrointestinal sys-
tem that lead to abnormal assimilation of 
food; but the mainly known cause of 
cachexia is cancer, which is responsible for 
the deaths of 22% of cancer patients. Can-
cer cachexia compromises quality of life 
and responses to anticancer therapies that 
result more toxic for patient, reducing 
survival. 
Muliawati et al. (3) in a clinical study distin-
guished two kinds of cachexia: primary 
and secondary. The first is produced by a 
tumor-induced metabolic change; where 
catabolism is accelerated and anabolism 
slowed. Cancer triggers a systemic inflam-
matory response that releases biochemical 
products. Everything brought to metabolic 
abnormalities, loss of appetite, and de-
crease of muscle and fat mass. The secon-
dary cachexia is caused by factors that 
compromise the normal food intake lead-
ing to malnutrition, nausea, vomiting, 
diarrhea and mechanical obstruction. In 
cancer cachexia, in general, there is a 
scenery similar to tissue inflammation: the 
liver protein synthesis switches from syn-
thesis of albumin to acute-phase proteins 
(c-reactive protein, fibrinogen α1-
antitrypsin). In this kind of cachexia, the 
acute-phase response is activated by cyto-
kines such interleukin-6 (IL-6), interleukin-
8 (IL-8), and tumor necrosis factor-α (TNF-
α) produced by host tissues or tumor cells; 
it does not involve loss of weight, and it is 
not sufficient to cause cachexia (4). 
 
Skeletal muscle wasting in cachexia 
This derangement involves muscle proteins 
and is characterized by a decrease in pro-
tein synthesis and an increase in protein 
catabolism.  
Protein synthesis is regulated by two key 
factors: eukaryotic initiation factor 2 (eIF2) 
and factor 4F (eIF4F). The first is associ-
ated with a pathway GTP/GDP-dependent 
and leads to an active translation, while 
there is a block of translation when eIF2 is 
phosphorylated. The latter drives to a cor-
rect starting of the translation; it results 
from the cooperation among eIF4E-4A-4G. 
In a cachectic subject there is an increase 
in the phosphorylation of eIF2 (5) and 
binding of eIF4E to 4E-BP1 (6), the constitu-
tive regulator of eIF4F complex. 
Protein catabolism may be due to the acti-
vation of the lysosomal system, cytosolic 
calcium-regulated calpains and mainly to 
the ATP ubiquitin-dependent proteolytic 
pathway. This degradation brings to loss of 
muscle fibers and later to atrophy. The 
lysosomal system is mainly responsible for 
the degradation of extracellular proteins 
and receptors. Pathways involving calpains 
attend in tissue injury and necrosis. The 
ubiquitin-proteasome pathway contributes 
to the degradation of myofibrillar proteins 
(7). 
The release of superoxide anions, hydro-
gen peroxides or nitric oxide can contrib-
ute to muscle wasting. These molecules 
can interact each other and generate more 
highly reactive products (Peroxynitrite and 
hydroxyl radical). This series of events can 
set off by an inflammatory event and they 
culminate in oxidative stress (8). The in-
crease of reactive oxidative species (ROS) 
promotes catabolism of muscle cells even 
more: study conducted in C2C12 cells 
documented that ROS induce an up-
regulation of E3-ubiquitin ligases (9), and 
accordingly grow up of proteasome activity 
and degradation of myosin. In cancer 
cachexia myosin heavy chain (MyHC) is an 
important target of muscle wasting. It is 
reduced in protein form but steady in 
mRNA level, as it was established with an 
experiment of Lenk et al. (10) where MyHC 
immunoprecipitated with ubiquitin. 
The fast-twitch type II fibers (in tibialis 
anterior and gastroecnemius) are lost 
faster than slow-twitch type fibers (in so-
leus). The reason is an increased degrada-
tive protein expression and protein oxida-
tion with decrease in anti-oxidant gene 
expression (11). In skeletal muscle there 
are two muscle-specific E3 ligases: atrogin-
1 and MuRF1(12). Both act on myofibrillar 
and intracellular proteins, labeling them 
for degradation through the ubiquitin-
proteosome system. Expression of atrogin-
1 and MuRF1 are regulated by IGF-I/PI3K/
Akt pathway, FoxO1 and 3, NFkB (12). 
Indeed muscle wasting is a direct conse-
quence of circulating proteins produced by 
both the host and tumour. 
Among these, a considerable factor is 
forkhead box class O (FoxO). In myotube, 
activation of FoxO3 stimulates protein 
degradation both lysosomal and protea-
some-dependent (11). Glucocorticoids 
contribute to FoxO activation decreasing 
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action of PI3K/Akt pathway that inactivates 
it by phosphorilation (10). It was high-
lighted in a study by Liu et al (13) on a 
cancer cachexia mice model, where the 
expression of FoxO1 in normal and 
cachectic mice was reduced using silenc-
ing oligonucleotides: this caused an in-
crease in skeletal muscle mass of the 
mice, an increase in the levels of MyoD 
and a decrease in the levels of Myostatin. 
Myostatin, a TGFβ suparfamily member, is 
the responsible factor for stopping growth 
of muscle tissue. Murine and human neo-
plasms further secrete it. It seems that 
myostatin is involved in the generation of 
cancer cachexia. Murine C26 colon cancer 
cells release a vast amount of myostatin, 
and experiments conducted with C2C12 
exposed to C26 conditional medium dem-
onstrated that the tumour mass produces 
such an amount of myostatin that can 
trigger skeletal muscle wasting (14). 
Probably because it blocks proliferation 
and differentiation of the cells, and in-
duces a decrease in MyoD levels. Skeletal 
muscle in C26 tumour bearing mice also 
displayed elevated activity of the auto-
phagy-lysosome pathway. In light of this 
Lokireddy et al. (12) asserted that 
“myostatin is a novel tumoral factor” . 
The loss of muscle mass is also affiliated 
to an increased serum level of a tumour 
produced proteolysis-inducing factor (PIF). 
Indeed an administration of PIF in normal 
mice brings to a rapid decrease in body 
weight and enhancement in mRNA of ubiq-
uitin in the gastroecnemius and compo-
nents 19S and 20S proteosome (15). PIF 





) that produces arachidonic 
acid (AA) that in turns actives NADPH oxi-
dase. This mechanism releases ROS and 
activates nuclear factor kappa B (NFkB) 
contributing to proteasomic degradation 
downstream (10). 
Also cytokines are involved in muscle wast-
ing. Costelli et al. (16), using inhibitors for 
TNF-α and IL-6 in rats bearing hepatoma, 
they prevented the depletion of muscle 
mass and reduced proteolysis (Figure1). 
Opposite to these negative factors, insulin-
like growth factor-1 (IGF1) can positively 
regulate muscle mass stimulating protein 
synthesis. 
A cachectic individual is also subjected to 
alterations in resting energy expenditure 
(REE) contributing to the energy deficit, 
therefore, to the wasting and the weight 
loss of the patients. Tumor presents low 
level of oxygen so the Krebs cycle and 
mitochondrial oxidative phosphorylation 
cannot have place. For this reason the 
great amount of glucose that tumor con-
sumes is converted in lactate. The latter is 




Cardiac muscle damage in cachexia 
Also the cardiac muscle may be damaged 
by cachexia. A statement of this assertion 
is in the study of Xu H et al. (17). In this 
research 24 CD2F1 mice were inoculated 
with an injection of colon 26 adenocarci-
noma cell suspension. Tumor was evident 
after seven days, and mice begin to die by 
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Figure 1. Skeletal muscle wasting in cachexia 
day 21. This experiment resulted in a de-
crease in the weight of gastroecnemius 
while heart weight remained stable; on the 
contrary, the expression of MAFbx and 
Bnip3 mRNAs was higher in tumor-bearing 
mice compared to controls. Similarly, left 
ventricular systolic diameter (LVSD) was 
increased, while diastolic posterior wall 
thickness was decreased significantly in 
tumor-bearing mice. Moreover, cardiomyo-
cytes isolated from tumor-bearing mice 
showed increased sarcomere contraction. 
 
Treatments 
The first attempt to reduce cachexia ef-
fects on lean mass reduction was to use 
appetite stimulants such megestrol ace-
tate, however gain in weight was due to an 
accumulation of fat rather than body mass 
(11). Another possibility was cyprohep-
tadine, a histamine antagonist; it improved 
in appetite but did not avoid weight loss. 
Corticosteroids were also used to enhance 
appetite, performance and sensation of 
well-being but they did not have positive 
effects on body weight (18). Neuropeptides 
regulate appetite, but they are still exam-
ined to understand its importance in the 
treatment of cancer cachexia. We know 
that growth hormone (GH) influences in a 
positive manner muscle mass but its clini-
cal efficacy has not been demonstrated yet 
(19). 
Moreover cachexia can be treated with an 
inhibitor of gene transcription of TNF 
(Pentoxifylline), with anti-cytokine antibod-
ies and cytokine receptor antagonists. Anti
-inflammatory/anabolic cytokine, like inter-
leukin-15 (IL-15), has a key role in a de-
crease in protein degradation and DNA 
fragmentation (20) . 
Until now the only treatment that brings 
good results in recovery of loss mass is 
exercise training. It may reduce pro-
inflammatory cytokine expression, mainly 
of TNF and IL-6 (19) and the expression of 






strength are also improved by exercise 
training (22). The anabolic component of 
exercise training involves the release of 
cytokine like IL-6, which inhibits TNF-α 
production, and it increases activation of 
antioxidant enzymes. Resistance training, 
moreover, induces significant phosphoryla-
tion on mTOR favouring protein synthesis 
(21). 
A regular physical activity can improve 
quality of life and it has positive effects on 
the chance of survival. Probably the effi-
cacy of exercise training is linked to the 
adult stem cells (ASC) of skeletal and car-
diac muscle tissue. 
 
Skeletal and cardiac muscle stem cells 
In the skeletal muscle tissue there are 
undifferentiated cells between the basal 
lamina and the plasma membrane. These 
cells are called “satellite cells” (SC) able to 
proliferate and differentiate when it needs: 
indeed they are involved in muscle growth 
and they have the possibility to repair 
skeletal muscle fibers after injury (9).  
Satellite cell frequency is different in the 
several fiber type muscle components. For 
example soleus muscle, predominantly 
composed of slow fibers, has more satel-
lite cells than fast fibers of extensor digito-
rum longus (EDL) muscle. In the differen-
tiation process of SC the MyoD family of 
the transcription factors comprehends 
mainly Myf5, MRF4, MyoD. The expression 
of the latter is absent in the quiescent 
phase, but it increases after external stim-
uli that actives cellular proliferation and 
differentiation. This signal is stopped by 
the interaction between MAFbx and MyoD, 
which led to proteasome degradation. For 
this reason MyoD-dependent differentia-
tion is negatively influenced by atrophy 
and increased oxidative stress (9). An im-
portant proliferative and differentiation 
factor is Pax7 (23) that is down-regulated 
by myostatin. Notch and bFGF also stimu-
late proliferation (23) while myogenin and 
MRF4 promote differentiation. 
Between cachexia and skeletal muscle SC 
there seems to be a strict correlation. Very 
recently it has been suggested that 
cachexia induced by congestive heart fail-
ure (CHF) and chronic kidney disease (CKD) 
may be caused by an increase in the levels 
of angiotensin II (Ang II) which reduces 
skeletal muscle regeneration via inhibition 
of satellite cell (SC) proliferation (24). 
On the other hand an exercise intervention 
increases the number of ASC in the muscle 
5-8 days after training (25,26). Muscle 
regeneration is activated by a maximal 
eccentric contraction that recreates an 
environment similar to an injury. Macaluso 
et al. (27) performed a study with healthy 
young male individuals, in the attempt to 
demonstrate that there is a different 
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amount of SC in the muscles of sedentary 
and active individuals. From this observa-
tion resulted that the higher stress in-
duced by a daily training in individuals 
with low VO
2
 max the amount of differenti-
ated stem cells was increased, while the SC 
pool size was decreased. These conditions 
were probably associated with a higher 
basal activation of p38-mitogen-activated 
protein kinase. This result probably de-
rived from the self-renewal capacity acti-
vated by both exercise training stress and 
injury. Hence, considering that in a cachec-
tic patient SC are impaired, exercise train-
ing may reduce muscle wasting counter-
acting the reduction in the proliferation 
state of SC.  
Despite many studies deal about skeletal 
stem cells, there are a few witnesses about 
cardiac stem cells yet. Until 90’ years, the 
scientific world thought that cardiomyo-
cytes were terminal cells without possibil-
ity to regenerate. Despite this Beltrami et 
al. in 2003 (28) isolated a little percentage 
of cardiac cells that showed a cardiac phe-
notype both in vitro and in vivo. These 
cardiac ASC have been widely studied by 
many research groups and ourselves (29-
35), but their biology, immunological fea-
tures, differentiation pathways are still 
unknown.  They are c-Kit-Sca1-MDR1 posi-
tive, they express cardiac troponin T and 
several cardiac sarcomeric proteins, typical 
of cardiac precursor cells (34). But also 
they express CD49, Connexin 43, Tro-
ponin T, OCT-4 and Nanog that are typi-
cally cardiac markers (36). Other studies 
demonstrated that these cells express also 
CD31 and CD34 like endothelial progeni-
tor cells (EPC), but only in the first three 
weeks from isolation (37). 
While a daily training may induce an in-
crease in the number of SC in the skeletal 
muscle, it is not known if it can induce 
also an increase in the number of cardiac 
progenitor cells in the myocardium, even if 
it may be supposed (26). We can expect 
that a physical activity could give benefits 
also in cardiac tissue, seen the common 
features between skeletal and cardiac 
tissue and the stimuli received by the car-
diac tissue during exercise training. 
 
Conclusions 
Muscle wasting of skeletal and cardiac 
tissues is an effect of cachexia, no cure 
exist for this at the moment. Only exercise 
training may ameliorate damages induced 
by cachexia like recovery of muscle mass. 
For this reason it would be desirable to 
understand the mechanisms underlying 
this phenomenon in order to recreate a 
possible pharmacological treatment that 
can mime its effects (exercise mimicking). 
Considering literature, one of the mecha-
nisms underlying recovery of muscle mass 
upon exercise in cachectic patients could 
be proliferation of ASC (38). This let us 
suppose that ASC may be used directly to 
replace damaged muscle fibers in cachectic 
patients, as many researcher’s groups are 
trying to do in clinical trials for muscular 
dystrophies or cardiac diseases. 
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